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Abstract
 .Transferrin Tf is required for proliferation of most cells, because cellular iron uptake is mainly mediated by binding of
 .  .Tf to its specific cell surface receptors TfR . The acute-phase protein a1-antitrypsin a1-AT completely inhibits binding
of diferric Tf to TfRs on human skin fibroblasts in a dose-dependent fashion. The inhibition is competitive as proved in
equilibrium saturation binding and kinetic studies. In saturation binding experiments a1-AT apparently increased the
 .  .dissociation constant K , but did not change the maximal density of binding sites B . As shown in kinetic studies,D max
this reduction of the affinity of Tf to its receptor caused by a1-AT was due to a decrease of the association rate constant
 .  .kq1 , whereas the dissociation rate constant ky1 remained unchanged. Furthermore, a1-AT almost completely
prevented internalization of the Tf–TfR complex. These interactions demonstrated biological implication, as a1-AT
reduced the proliferation of human fibroblasts up to maximal 30% of control. The inhibitory potency of a1-AT was already
seen in physiologic concentrations; the maximal effect, however, was achieved at concentrations above the normal range,
which are attained in the course of inflammation and infection. Therefore, we suppose that a1-AT as an endogenous factor
modulates the complex mechanism of fibrogenesis not only by its known antiproteolytic function but also by inhibiting the
proliferation of fibroblasts. q 1998 Elsevier Science B.V.
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1. Introduction
Iron is an essential element for all living organisms
because of its importance in several biological reac-
tions, such as DNA synthesis by regulating the key
w xenzyme ribonucleotide reductase 1 , oxidative phos-
w xphorylation 2 and in normal mitochondrial electron
transport. Cellular iron uptake is mainly mediated by
 .the binding of diferric transferrin Tf , the main iron
transport protein in human plasma, to specific cell-
) Corresponding author. Fax: q43 512 504 4052.
 . w xsurface transferrin receptors TfR 3 . The formed
Tf–TfR complex is endocytosed into the cells, where
iron is released after acidification of the endocytic
w xvesicle, and the receptor then recycled 4 .
Recently, we have shown that a1-antitrypsin a1-
.AT , a 56 kDa plasma glycoprotein, inhibits Tf-bind-
w xing to its receptor on human placenta membranes 5
and modulates iron metabolism in erythroid and
w xmonocytic cell lines 6,7 . a1-AT is one of the
several biochemically different acute-phase proteins,
which are distinctly increased in response to inflam-
mation, infection and malignant disease. a1-AT is
0167-4889r98r$19.00 q 1998 Elsevier Science B.V. All rights reserved.
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w xmainly produced in hepatocytes 8,9 , but also in
w xmacrophages and monocytes 10 . Its synthesis is
primarily stimulated by the proinflammatory cytokine
w xInterleukin 6 9,11,12 , additionally by transforming
 . w xgrowth factor b1 TGFb1 13 , by bacterial lipo-
w xpolysaccharide 11 and, interestingly, by itself when
in complex with neutrophil elastase mediated via the
 . w xserpin–enzyme-complex SEC receptor 14 . In its
main function a1-AT is a member of the serpin
family, the predominant inhibitors of neutrophil elas-
w xtase and of other proteases 15 . As shown by the
consequences of deficiencies in specific serpins, these
proteins play an important role in the control of
proteolytical cascade systems, such as fibrinolysis
and coagulation, by limiting tissue destruction and
initiating tissue repair at the sites of injury and
w xinflammation 16 .
The present study was designed to investigate the
effect of a1-AT on TfR binding in human skin
fibroblast. Former studies demonstrated that normal
human skin fibroblasts, cultured in vitro, exhibit
w xbinding sites for Tf 17–19 . To test whether this
interaction of a1-AT has biological implications, as
w xalready shown for erythroid and monocytic cells 6,7 ,
we studied the effect of a1-AT on the proliferation
of fibroblasts in an attempt to show whether a1-AT
demonstrates another, yet undescribed, influence on
the complex mechanism of fibrogenesis.
2. Materials and methods
2.1. Materials
w125 x Human I transferrin specific activity approxi-
.mately 1000 Cirmmol was obtained from Amer-
 .sham Amersham, Bucks, UK and iron saturated as
w xdescribed previously 20 . Human a1-antitrypsin was
obtained from C.R.T.S. Lille, France. a1-AT was
characterized by isoelectric focusing phenotype
.MM , the concentration was measured by nephelome-
try and the degree of purity was ;98%, as estimated
by immunoelectrophoresis with only a minor contam-
ination from albumin. Human diferric transferrin and
apotransferrin were purchased from Sigma Munich,
.  .Germany . Medium M199 and fetal calf serum FCS
were obtained from Biological Industries Beth
.Haemek, Israel . Sources for other substances were
w xreported earlier 5–7 .
2.2. Methods
2.2.1. Cell culture
Human skin fibroblasts were isolated from human
skin fragments kindly provided by N. Romani, Dept.
.of Dermatology, University of Innsbruck and uti-
lized in passages 3 to 8. Fibroblast monolayers were
grown in M199 supplemented with 10% FCS in
175 cm2 plastic tissue culture flasks and cultured in a
humidified incubator at 378C and 5% CO . After2
reaching confluence the cells were subcultured and
reseeded at a ratio of 1:3. Cell viability was deter-
mined by exclusion of 0.1% trypan blue and was
greater than 95% for all experiments.
2.2.2. Binding assays
All equilibrium inhibition binding experiments and
kinetic studies were performed in 16 mm tissue cul-
 .ture wells Costar, Cambridge, MA . Fibroblasts were
generally seeded five days prior to experiment. At the
time of the experiment, culture wells were covered by
a near confluent layer of cells with a count of about
5=105 cellsrwell. Prior to the experiments fibrob-
lasts were washed with incubation buffer RPMI
 .1640q0.5% bovine serum albumin BSA q10 mM
.Hepes at 48C, and then incubated with a constant
w125 x amount of I transferrin ranging from 0.25–
.0.55 nM in a final assay volume of 0.5 ml. Non-
specific binding was determined by the addition of
1 mM diferric transferrin and ranged from 10–15% of
specific binding. After incubation at 378C for 60 min
 .gassed with 95% O and 5% CO at 48C for2 2
 .120 min or the time indicated kinetic studies the
reaction was stopped with the addition of 2 ml ice-cold
 .phosphate buffered saline PBS . After excess ligand
had been washed off twice with PBS, the fibroblasts
were solubilized with 1 N NaOH and radioactivity
was measured with a LKB 1282 compugamma
counter.
To distinguish cell surface-bound from internalized
w125 xI transferrin, we treated preincubated cells with
w xpronase as described in detail elsewhere 20 .
2.2.3. Proliferation assay
 3 .Fibroblasts were seeded 7.5=10 cellsrwell
onto 96-well microtiter plates, allowed to adhere for
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24 h and cultured in M199 with 0.5% FCS. This
incubation under serum-starved conditions deprives
the cells of serum-associated mitogens, arrests growth
and synchronizes cell proliferation in response to
w xmitogens being subsequently assayed 21 . After 48 h
the medium from each well was replaced with M199
supplemented with 20% FCS optimal growth condi-
.tions and increasing concentrations of a1-AT were
added. After a further 48 h incubation fibroblast pro-
liferation was assessed using a colorimetric assay
w based on tetrazolium salt MTT 3- 4,5 dimethyl-di-
. xazol-2-yl -2.5-diphenyl tetrazolium bromide as de-
w xscribed previously 22 . At the end of the incubation
period a stock solution of MTT was added to each
well of the microtiter plate. After 6 h the medium was
aspirated, dimethylsulfoxide added to each well to
dissolve formazan crystals and absorbance was mea-
sured at 570 nm using a microplate spectrophotom-
 .eter. Controls negativerpositive consisted of M199
supplemented with 0.5% or 20% FCS, respectively.
2.2.4. Data analysis
Binding inhibition experiments were analysed by
w xnon-linear algorithms as described 23 . Equilibrium
saturation parameters were obtained by Scatchard
transformation. Kinetic studies were calculated by
using the second order rate equation as described
w x21 . Unless otherwise indicated, data are given as
means"S.E.M. of n determinations.
3. Results
3.1. Effects of a1-AT on binding and internalization
[125 ]of I transferrin
As depicted in Fig. 1, a1-AT inhibited binding of
w125 xI transferrin to its receptor on fibroblasts with a k i
 .value of 1.56"0.46 mM ns4 . Inhibition was ap-
parently monophasic pseudo-Hill coefficient: y0.92
."0.08 and was complete down to the non-specific
binding definition. Lowering the incubation tempera-
ture to 48C did not change the k value 2.13"i
. 0.15 mM or the pseudo-Hill coefficient hsy0.94
."0.03 significantly. Testing other acute phase pro-
teins, only a2-macroglobulin demonstrated an in-
hibitory potency, but only partially to 39"6% of
w125 xFig. 1. Inhibition profile of I transferrin binding to its receptor
by a1-AT on human skin fibroblasts. Human skin fibroblasts at
5 .a density of about 5=10 cellsrdish were incubated in an assay
w125 xvolume of 0.5 ml with a constant concentration of I transferrin
 .varying from 0.25–0.55 nM in the presence of increasing con-
 .  .centrations of diferric transferrin I , a1-AT ^ , a2-macro-
 .  .globulin e or C-reactive protein ‘ for 60 min at 378C. The
values are taken from four different experiments, each of which
was performed in duplicate.
control at a maximal concentration of 10 mM Fig.
.1 . Haptoglobin, C-reactive protein or ferritin, showed
w125 xno inhibitory effect on I transferrin binding.
Binding inhibition studies with unlabelled diferric
Tf at 378C yielded a k value of 2.13"0.15 nM andi
 .a pseudo-Hill coefficient of y0.83"0.04 ns5 .
Again, lowering the incubation temperature did not
  ..alter the k value 1.67"0.12 nM ns3 as well asi
 .the pseudo-Hill coefficient y1.09"0.07 signifi-
cantly.
The pronase technique was used to discriminate
between surface membrane-bound and internalized
w125 xI transferrin. Fibroblasts were incubated with
w125 xI transferrin at 48C and 378C and after washing off
excess unbound ligand the cells were treated with
0.25% pronase for 60 min at 48C. Only 0.75"0.53%
w125 xof bound I transferrin at 48C was detected in the
 .final pellet, whereas 65.5 " 1.5% n s 3 was
pronase-resistant after incubation at 378C and de-
tected in the pellet, which is equivalent to internal-
w125 xized I transferrin. Addition of 100 mM a1-AT
yielded an almost complete inhibition of Tf internal-
  ..ization 2.4"1.3% of control ns3 .
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w125 xFig. 2. Scatchard analysis of binding of I transferrin to human
skin fibroblasts in the presence of 5mM a1-AT. Human skin
w125 xfibroblasts were incubated with I transferrin at various spe-
cific activities from 1000Cirmmol to 10 Cirmmol, by addition
 .of unlabelled diferric Tf, in either the presence n or absence
 .I of 5mM a1-AT for 60min at 48C in an incubation buffer
including 0.5% BSA. Linear regression analysis of the parame-
 .ters yielded the following data: control I : K s1.70"D
 .0.17 nM, B s22365"2481 sitesrcell; q5mM a1-AT n :max
K s7.16"1.56 nM, B s21343"1069 sitesrcell. The re-D max
sults are given as mean"S.E.M. of four independent studies
performed in duplicate.
3.2. a1-AT effect on equilibrium saturation binding
studies
In equilibrium saturation binding studies
w125 xI transferrin bound to fibroblasts with a K valueD
 .of 1.99"0.12 nM ns4 and a maximal density of
 .binding sites B of 43705"5623 sitesrcell,max
which is equivalent to 11.61"1.50 ng Tfr106 cells.
When incubation was carried out at 48C, the K D
 .value remained unchanged 1.70"0.17 nM, ns3 ,
whereas B was reduced to 22365"2481 or 6.17max
"0.80 ng Tfr106 cells, which is due to restriction to
surface receptor binding only.
As shown in Fig. 2, the addition of 5mM a1-AT
to saturation binding studies at 48C distinctly de-
w125 xcreased the affinity of I transferrin to its receptor
by increasing the K value to 7.16"1.56 nM, butD
did not alter the B value 21343"1039 sitesrcell,max
.ns3 .
Using an incubation buffer without BSA for equi-
librium saturation binding experiments at 48C the
Scatchard analysis showed a biphasic plot with a
high-affinity and low-affinity binding site and yielded
the following K values and maximal density ofD
binding sites: high affinity: K s1.24"0.19 nM,D
Fig. 3. Effects of a1-AT on the association and dissociation
w125 x  .kinetics of I transferrin-binding to human skin fibroblasts. A
Association and dissociation kinetics. Human skin fibroblasts
w125 xwere incubated with a constant concentration of I transferrin
 .for the times indicated, either alone I or in the presence of
 .5mM a1-AT n . The calculated association rate constant, kq1,
6 y1  .was 9.22"0.15=10 Mmin 0–10 min, r s0.95 for control
6 y1  .conditions and 2.21"0.85=10 Mmin 0–15 min, r s0.96
in the presence of a1-AT. Dissociation was initiated after 60 min
 .of incubation by the addition of 1mM diferric Tf alone I or
 .  .together with 5mM a1-AT ‘ . B Semilogarithmic plot of
 .wln B rB bound ligand measured for the indicated timet e
 .  .xB rbound ligand B vs. time. Dissociation rate constants,t e
ky1, were calculated by linear regression and yielded the fol-
 . y1 lowing data: 1mM diferric Tf alone I 0.1008 min r s
.  . y1 y0.98 ; in the presence of a1-AT ‘ 0.1065 min r s
.y0.97 . The values shown are means of three different experi-
ments performed in duplicate.
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B s17045"2403 sitesrcell; low affinity: K smax D
18.36"1.99 nM, B s239957"28538 sitesrcellmax
 .ns3 . In the presence of 5mM a1-AT only the K D
value of the high affinity binding site was increased
 .5.18"0.33 nM . The K value of the low-affinityD
binding site and the number of TfR for both binding
 .sites were not changed by a1-AT data not shown .
3.3. Effects of a1-AT in kinetic studies
w125 xIn kinetic studies at 378C, I transferrin bound to
TfR on human fibroblasts with an association rate
 . 6 y1 constant kq1 of 9.22"0.15=10 M min ns
.3 . In the presence of 5mM a1-AT the kq1 value
6 y1 was decreased to 2.21"0.85=10 M min Fig.
 ..3 A . After reaching equilibrium, the addition of
1 mM diferric Tf led to an apparently monophasic
decay of ligand–receptor complex with a dissociation
 . y1 rate constant ky1 of 0.1008"0.0171 min ns
.  .3 t s6.9 min . In contrast to association, addi-1r2
tion of 5 mM a1-AT did not change the dissociation
 y1rate constant ky1s0.1065"0.006 min , ns3;
.   .  ..t s6.5 min Fig. 3 A and B .1r2
Fig. 4. Effect of a1-AT on proliferation of human skin fibrob-
lasts. Human skin fibroblasts made quiescent in 0.5% FCS were
switched to fresh 20% FCS when increasing concentrations of
 .a1-AT ranging from 10 nM to 100 mM were added as described
in detail in Section 2. The MTT assay was carried out after an
incubation of 48 h. Values represent the mean"S.E.M. of the
optical density measured at different concentrations of a1-AT
minus optical density of the positive control M199 medium in
.the presence of 20% FCS of eight independent experiments
 w x .OD positive control s0.515"0.009 . Mean optical density of
 .negative control M199 medium in the presence of 0.5% FCS
was 0.371"0.011.
3.4. Effects of a1-AT on TfR expression
Saturation binding assays, performed at 48C on
fibroblasts, which were pretreated with 50 mM a1-AT
for three days and afterwards washed, showed that
the maximal density of binding sites for Tf was
significantly increased from 22365"2481 sitesrcell
 . to 40048"5083 sitesrcell ns4 P-value-0.01,
.Student’s t-test .
3.5. Effects of a1-AT on cell proliferation
When fibroblasts were incubated under optimal
growth conditions M199 supplemented with 20%
.FCS with increasing concentrations of a1-AT
 .10 nM to 100 mM for 48 h, we found that a1-AT
significantly reduced the proliferation of fibroblasts
in a dose-dependent manner up to maximal 30.56"
 .  .3.41% of control ns8 Fig. 4 .
4. Discussion
In previous studies we have shown that the acute-
phase protein a1-AT inhibited the growth and prolif-
eration of erythroid cell line by interfering with Tf-
w xmediated iron uptake 6 . The purpose of the present
study was to investigate whether a1-AT shows simi-
lar effects on human skin fibroblasts, as there is
evidence that a1-AT plays an important role in
fibrogenesis by limiting destruction and by initiating
tissue repair at the sites of injury and inflammation.
In binding inhibition studies on fibroblasts, a1-AT
w125 xcompletely inhibited binding of I transferrin to its
 .receptor in a dose-dependent manner Fig. 1 . As
shown in kinetic studies and equilibrium saturation
binding experiments this inhibition was competitive.
The addition of a1-AT caused a distinct decrease of
the association, but did not change the dissociation in
  .  ..kinetic studies Fig. 3 A and B . Consequently, in
saturation experiments the K value was increasedD
by a1-AT, demonstrating decreasing affinity of the
ligand to its receptor, but no change in the maximal
 .density of binding sites was detected Fig. 2 . This is
consistent with our previous studies, in which we
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demonstrated that a1-AT interferes with TfR-binding
w xin a direct competitive fashion 5,6 . The possibility
of an alteration of the configuration of the Tf molecule
by a1-AT was rejected by the exclusion of specific
w xbinding of a1-AT to the Tf molecule 5 . Further-
more, the addition of a1-AT did not cause a change
in the protein pattern of Tf nor a difference in the
w xisoelectric point 5 . Moreover, as a1-AT did not
lose its inhibitory activity by lowering the incubation
temperature to 48C, a change in the molecular mobil-
ity of the membrane surface and its receptors andror
a change in the fluidity of surrounding membrane
lipids can be excluded. Therefore, we suggest that
a1-AT competes directly with Tf for the receptor
site. Kinetic and saturation experiments Figs. 2 and
 .  ..3 A and B provide further support for this as-
sumption. Our data obtained from saturation binding
and from kinetic studies are in general agreement
with previous results from experiments performed
w xwith fibroblasts 17,18 .
Performing the saturation binding studies without
BSA, we found a biphasic Scatchard plot with two
w125 xbinding sites of I transferrin, a high- and a low-af-
finity component. This fact was already described in
reports using the erythroleukaemic cell line K562 and
w xisolated hepatocytes 24,25 . These studies showed
that all or at least the major part of iron uptake is
mediated by the high-affinity site. The low-affinity
component was completely inhibited by the addition
w xof albumin 24,25 . Also in our experiments, the
low-affinity site was completely blocked by albumin
and the B of the high-affinity binding site wasmax
identical with the number of surface receptors from
studies performed in 0.5% BSA. a1-AT interfered
only with the high-affinity component and demon-
strated no effect on the low-affinity site results not
.shown .
Using the pronase technique we showed that about
w125 x65% of I transferrin, bound at 378C, is internal-
ized and that a1-AT almost completely inhibited the
internalization of the diferric Tf–TfR-complex.
There is much evidence that iron deprivation either
w xby inhibiting Tf-mediated iron uptake 26,27 or by
wchelating intracellular iron with desferrioxamine 28–
x30 may reduce cell growth and proliferation, espe-
cially of malignant cells. In accordance with our
w xprevious studies with K562 cells 6 , a1-AT signifi-
cantly reduced the proliferation of fibroblasts in a
dose-dependent fashion up to maximal 30.6"3.4%
 .of control Fig. 4 . Interestingly, in a former study,
anti-TfR-monoclonal antibodies, which interfere with
Tf at the receptor level, did not reduce the prolifera-
tion of fibroblasts prepared from Tenon’s capsule.
This paper, however, does not show whether Tf
binding to its receptor is inhibited by the monoclonal
w xantibodies used 31 . Moreover, it has recently been
reported that, in contrast to a1-AT, the monoclonal
anti-TfR-antibodies demonstrated a maximal 75% in-
hibitory effect on TfR binding, and they only mod-
w xestly inhibited tumor cell proliferation in vitro 32 .
Combinations of various monoclonal antibodies,
however, enhanced the inhibitory potency on prolifer-
w xation 27 . Therefore, we propose that the monoclonal
anti-TfR antibodies used in the paper by Smyth et al.
w x31 were not sufficient enough to deplete intra-
cellular iron and consequently inhibit the prolifera-
tion of fibroblasts.
Analogous to other studies with several cell sys-
tems, in which iron deprivation causes an upregula-
w xtion of TfR 29,33,34 , cell treatment with a1-AT for
three days induced a significant increase of TfR in
fibroblasts.
Testing other acute phase proteins, only a2-
macroglobulin showed a partial inhibition of about
40%. Because of its high molecular weight, the ac-
tion of this protein is restricted to blood circulation
w x35 , in contrast to a1-AT, which is able to penetrate
w xinto tissue 36 . Therefore, we suppose that a2-
macroglobulin’s effect on TfR-binding might not be
of physiological significance. Interestingly, the syn-
w xthesis of a1-AT is also regulated by TGFb1 8 , a
key fibrogenic growth factor that enhances extracellu-
lar matrix deposition and inhibits collagenase activi-
w xties 37 .
It is noteworthy to mention that the inhibitory
effect of a1-AT on Tf-binding to its receptor was
already seen in low physiological concentrations
 .normal range 20–40 mM . Maximal inhibition of
TfR binding and reduction of fibroblast proliferation,
however, were attained at concentrations above the
normal range, which are achieved in the course of
inflammation and infection.
In summary, we have found that the acute-phase
protein a1-AT demonstrates an effect on iron
metabolism of human skin fibroblasts that has not
been described heretofore. a1-AT completely inhib-
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ited TfR binding and internalization of the Tf–TfR
complex in a dose-dependent and competitive fash-
ion. This interaction led to a reduction of cell prolif-
eration. These findings suggest that the acute-phase
protein a1-AT modulates the cascade of fibrogenesis
not only by its antiproteolytic function as a member
of the serpin family but also by inhibiting the prolif-
eration of fibroblasts. Therefore, we suppose that
a1-AT acts as an endogenous antifibrotic agent and
inhibitor of excessive fibrogenesis, for instance, in
the course of the wound healing process and liver
fibrosis.
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